Repetitive Exposure of Pancreatic Islets to Interleukin-1β. AnIn VitroModel of Pre-diabetes?
- 1 January 1991
- journal article
- research article
- Published by Taylor & Francis in Autoimmunity
- Vol. 10 (4) , 311-318
- https://doi.org/10.3109/08916939109001905
Abstract
The slowly progressing loss of glucose tolerance over years before clinical onset of Type 1 (insulin-dependent) diabetes mellitus may be due to repetitive immunological attacks on the pancreatic beta-cell mass. Accordingly, we studied the effects of repetitive exposure of isolated rat pancreatic islets to the beta-cytotoxic immune-mediator interleukin-1β. Islets were exposed thrice to 60 U/ml of recombinant interleukin-1β for 24 hr. The islets were allowed to recover for 6 d between the interleukin-1β exposure periods. After each of the three interleukin-1β exposure periods, islet capacity to release insulin was decreased to 12, 6 and 3% of control, respectively, and islet insulin content decreased to 75, 56 and 21%, respectively. After the two recovery culture periods, the capacity for insulin release reversed to 75 and 30% of control, respectively. An increase in islet insulin content was only seen after the first recovery culture. During repetitive as well as long-term (6 d) interleukin-1β exposure of islets, medium accumulation of glucagon was either increased or unaffected. In analogy, beta-cells exposed to interleukin-1β for 6 d showed ultrastructural signs of degeneration and cytolysis, whereas alpha-cells were intact. In conclusion, interleukin-1β injury to beta-cells was partially reversible, but successive episodes of islet interleukin-1β exposure were increasingly detrimental; alpha-cell function and structure did not show susceptibility to damage by interleukin-1β. These findings may contribute to our understanding of islet cell behaviour before and during onset of Type 1 diabetes.Keywords
This publication has 18 references indexed in Scilit:
- Cloning and expression of an interleukin‐1β precursor and its conversion to interleukin‐1βFEBS Letters, 1989
- Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin SecretionDiabetes, 1988
- Interleukin-1 Inhibits Glucose-Modulated Insulin and Glucagon Secretion in Rat Islet Monolayer Cultures*Endocrinology, 1988
- Inhibitory Effects of Interleukin 1 on Insulin Secretion, Insulin Biosynthesis, and Oxidative Metabolism of Isolated Rat Pancreatic Islets*Endocrinology, 1987
- Aberrant expression of Class II major histocompatibility complex molecules by B cells and hyperexpression of Class I major histocompatibility complex molecules by insulin containing islets in Type 1 (insulin-dependent) diabetes mellitusDiabetologia, 1987
- Pancreatic B cells possess defense mechanisms against cell-specific toxicity.Proceedings of the National Academy of Sciences, 1986
- Type I Diabetes MellitusNew England Journal of Medicine, 1986
- Regulation of glucagon release: Effects of insulin on the pancreatic A2-cell of the guinea pigDiabetologia, 1979
- EFFECTS OF PREGNANCY IN THE RAT ON THE SIZE AND INSULIN SECRETORY RESPONSE OF THE ISLETS OF LANGERHANSJournal of Endocrinology, 1972
- Determination of total serum insulin (IRI) in insulin-treated diabetic patientsDiabetologia, 1972